The Science

Continuous Cardiac Biomarker Surveillance

A new paradigm in cardiac diagnostics — moving from episodic laboratory measurement to real-time, continuous biochemical monitoring at the point of care.

The Clinical Gap

Serial Troponin Draws Are an Incomplete Model

Cardiac troponin is the gold standard biomarker for detecting myocardial injury. The current diagnostic model depends on serial venous blood draws taken hours apart. Between draws, the patient is biochemically unmonitored — subclinical elevations, transient spikes, and early injury signals go undetected.

Patient clutching chest with cardiac symptoms

Step 1

Symptom Onset

Patient presents with cardiac symptoms

No Data

Nurse performing blood draw venipuncture on patient arm

Step 2

Blood Draw 1

First troponin sample at presentation

3hr Gap

Blood vials and test tubes in laboratory rack

Step 3

Blood Draw 2

Repeat draw at 3 hours post-presentation

3hr Gap

Doctor reviewing troponin lab results and patient data

Step 4

Blood Draw 3

Diagnosis

Final sample at 6h, results interpreted

Between each draw, the patient is biochemically unmonitored.

Subclinical elevations, transient spikes, and early injury signals go undetected until the next scheduled sample.

The Opportunity

Continuous monitoring eliminates the diagnostic blind spots inherent in serial sampling

Every hour of delay in cardiac diagnosis increases mortality risk. Our platform is designed to collapse that timeline.

Our Approach

From Discrete Sampling to Continuous Surveillance

Alycium's lead program, ALC-100, is a continuous point-of-care cardiac troponin monitoring platform. The system is engineered to provide uninterrupted troponin measurement without the need for repeated venipuncture or laboratory processing.

The platform is designed to detect troponin elevations as they occur — collapsing the diagnostic delay inherent in serial draw protocols and enabling real-time clinical decision-making.

Continuous troponin measurement without serial venipuncture
Point-of-care deployment — no central laboratory dependency
Real-time data output for immediate clinical interpretation
Designed for integration with existing clinical workflows
Engineered for high-sensitivity detection thresholds

The capabilities described above reflect design objectives for an investigational device that has not been cleared or approved by the FDA. Actual performance may differ from design targets.

Biosensor Interface

Proprietary sensor array engineered for continuous cardiac troponin detection

Signal Processing

On-device signal amplification, noise reduction, and analyte quantification

Real-Time Output

Continuous troponin data delivered to the clinical interface

Clinical Decision

Threshold-based alerting and trend analysis to support rapid intervention

Platform architecture is illustrative and represents design intent for an investigational system. Final device configuration is subject to change based on development outcomes and regulatory requirements.

Clinical Significance

Why Continuous Monitoring Matters

Acute myocardial infarction remains the leading cause of death globally. Time to diagnosis directly correlates with clinical outcome — every hour of delay in reperfusion therapy increases mortality risk.

Current troponin assays, even high-sensitivity variants, are constrained by the serial sampling model. The result is a diagnostic process that is inherently discontinuous, introducing latency at every stage.

Continuous cardiac biomarker surveillance eliminates these gaps. Clinicians gain the ability to detect injury at the earliest possible point — potentially before the patient meets conventional diagnostic criteria.

Reduce time from myocardial injury to clinical detection
Enable trend-based diagnostics over static threshold interpretation
Support earlier initiation of evidence-based interventions
Provide continuous risk stratification in high-acuity settings

Beyond Troponin

A Modular Platform, Not a Single Device

The technology architecture underlying ALC-100 is designed as a modular surveillance platform. Our development roadmap extends across four cardiac biomarker programs — each leveraging shared architecture while addressing a distinct unmet clinical need.

View Full Pipeline →

Platform modularity is a design objective. There is no guarantee that the architecture developed for ALC-100 will be technically or commercially applicable to additional analytes or indications.